Daiichi Sankyo trims AnGes gene therapy partnership
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas returned to originator AnGes MG its exclusive US and European marketing rights to the gene-based therapy Collategene (beperminogene perplasmid), citing a review of its development portfolio.